November 25, 2019
1 min read

Canada recommends Verkazia reimbursement

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

The Canadian Drug Expert Committee has issued a reimbursement recommendation for Verkazia eye drops, a treatment for severe vernal keratoconjunctivitis, according to a press release.

Verkazia (cyclosporine 0.1% topical ophthalmic emulsion, Santen) is indicated for children from the age of 4 years through adolescence.

The final decision on public reimbursement will be made by provincial jurisdictions, the release said.